Sanofi (SNY)
After hours:
| Previous Close | 47.69 |
| Open | 47.56 |
| Bid | 39.94 x 100 |
| Ask | 46.72 x 200 |
| Day's Range | 46.31 - 47.57 |
| 52 Week Range | 42.63 - 56.26 |
| Volume | |
| Avg. Volume | 1,929,487 |
| Market Cap | 118.154B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 20.35 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.04 (4.37%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-Sanofi Q1 profit slips on generic competition, forex effects
Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent. The company reiterated it expects 2024 adjusted earnings per share (EPS) to slip by a "low single-digit" percentage, excluding currency swings, citing higher taxes and an increase in development expenditure. Finance chief Francois-Xavier Roger said in a media call that the decline in the Argentine Peso was a particular drag on first-quarter overseas sales.
- Reuters
Sanofi Q1 profit slips on generic competition, forex effects
(Reuters) -Sanofi reported on Thursday that its first-quarter operating income declined 14.7%, as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent. The company reiterated it expects 2024 adjusted earnings per share (EPS) to slip by a "low single-digit" percentage, excluding currency swings, citing higher taxes and an increase in development expenditure. Finance chief Francois-Xavier Roger said in a media call that the decline in the Argentine Peso was a particular drag on first-quarter overseas sales.
- Zacks
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
